Company Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Country | Bermuda |
Founded | 2015 |
IPO Date | May 24, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 297 |
CEO | Sanj K. Patel |
Contact Details
Address: 23 Old Bond Street, Floor 3 London, X0 WIS 4PZ United Kingdom | |
Phone | 7814319100 |
Website | kiniksa.com |
Stock Details
Ticker Symbol | KNSA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001730430 |
CUSIP Number | G5269C101 |
ISIN Number | BMG5269C1010 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Sanj K. Patel | Chief Executive Officer and Chairman of the Board |
Eben Tessari | Senior Vice President and Chief Operating Officer |
Dr. John F. Paolini | Senior Vice President and Chief Medical Officer |
Mark Ragosa C.F.A. | Senior Vice President and Chief Financial Officer |
Michael R. Megna CPA | Chief Accounting Officer and Group Vice President of Finance |
Mei Jang | Senior Vice President of Technical Operations |
Rachel Frank | Associate Director of Investor Relations |
Chad Morin | Senior Vice President and Chief Compliance Officer |
Madelyn Demsky Zeylikman | SVice President, General Counsel and Secretary |
Melissa Manno | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 28, 2024 | EFFECT | Notice of Effectiveness |
Jun 28, 2024 | 15-15D | Filing |
Jun 28, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Jun 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jun 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jun 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jun 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jun 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jun 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jun 28, 2024 | POS AM | Post-Effective amendments for registration statement |